Detalhe da pesquisa
1.
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission.
Blood
; 143(5): 417-421, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37879077
2.
Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis.
Cancer
; 122(23): 3650-3656, 2016 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27479888
3.
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
medRxiv
; 2023 Dec 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38106221